Provectus and POETIC, The Pediatric Oncology Experimental Therapeutics Investigators Consortium, a group of top-tier academic medical centers developing new pediatric cancer therapies, entered into a joint research agreement focused on pediatric applications of PV-10, an investigational oncolytic immunotherapy, as a potential treatment for childhood cancers. The program will involve collaboration with a number of NCI Cancer Centers that are part of the POETIC group including Memorial Sloan Kettering Cancer Center (MSK), Alberta Children's Hospital, and other top-tier cancer centers of excellence.